Li Hong-Xia, Gong Yu-Wen, Yan Pi-Jun, Xu Yong, Qin Gang, Wen Wei-Ping, Teng Fang-Yuan
Department of Otolaryngology Head and Neck Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Department of Otolaryngology, Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Front Immunol. 2024 Nov 29;15:1453753. doi: 10.3389/fimmu.2024.1453753. eCollection 2024.
Head and neck squamous cell carcinoma (HNSCC) is a prevalent malignant tumor globally. Despite advancements in treatment methods, the overall survival rate remains low due to limitations such as poor targeting and low bioavailability, which result in the limited efficacy of traditional drug therapies. Nanomedicine is considered to be a promising strategy in tumor therapy, offering the potential for maximal anti-tumor effects. Nanocarriers can overcome biological barriers, enhance drug delivery efficiency to targeted sites, and minimize damage to normal tissues. Currently, various nano-carriers for drug delivery have been developed to construct new nanomedicine. This review aims to provide an overview of the current status of HNSCC treatment and the necessity of nanomedicine in improving treatment outcomes. Moreover, it delves into the research progress of nanomedicine in HNSCC treatment, with a focus on enhancing radiation sensitivity, improving the efficacy of tumor immunotherapy, effectively delivering chemotherapy drugs, and utilizing small molecule inhibitors. Finally, this article discussed the challenges and prospects of applying nanomedicine in cancer treatment.
头颈部鳞状细胞癌（HNSCC）是全球一种常见的恶性肿瘤。尽管治疗方法有所进步，但由于靶向性差和生物利用度低等局限性，总体生存率仍然较低，这导致传统药物疗法的疗效有限。纳米医学被认为是肿瘤治疗中一种很有前景的策略，具有实现最大抗肿瘤效果的潜力。纳米载体可以克服生物屏障，提高药物向靶向部位的递送效率，并将对正常组织的损伤降至最低。目前，已开发出各种用于药物递送的纳米载体来构建新型纳米医学。本综述旨在概述HNSCC治疗的现状以及纳米医学在改善治疗效果方面的必要性。此外，还深入探讨了纳米医学在HNSCC治疗中的研究进展，重点是提高放射敏感性、改善肿瘤免疫治疗疗效、有效递送化疗药物以及利用小分子抑制剂。最后，本文讨论了应用纳米医学进行癌症治疗的挑战和前景。
